WO2021128272A1 - 一种细菌纤维素-聚氨酯复合材料及其制备方法和应用 - Google Patents
一种细菌纤维素-聚氨酯复合材料及其制备方法和应用 Download PDFInfo
- Publication number
- WO2021128272A1 WO2021128272A1 PCT/CN2019/129157 CN2019129157W WO2021128272A1 WO 2021128272 A1 WO2021128272 A1 WO 2021128272A1 CN 2019129157 W CN2019129157 W CN 2019129157W WO 2021128272 A1 WO2021128272 A1 WO 2021128272A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bacterial cellulose
- composite
- microfibers
- composite material
- weight
- Prior art date
Links
- 239000002131 composite material Substances 0.000 title claims abstract description 126
- 229920002635 polyurethane Polymers 0.000 title claims abstract description 68
- 239000004814 polyurethane Substances 0.000 title claims abstract description 68
- 230000001580 bacterial effect Effects 0.000 title claims abstract description 53
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- 229920002749 Bacterial cellulose Polymers 0.000 claims abstract description 207
- 239000005016 bacterial cellulose Substances 0.000 claims abstract description 207
- 229920001410 Microfiber Polymers 0.000 claims abstract description 107
- 239000003658 microfiber Substances 0.000 claims abstract description 107
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 80
- 229920005830 Polyurethane Foam Polymers 0.000 claims abstract description 57
- 239000011496 polyurethane foam Substances 0.000 claims abstract description 57
- 239000003960 organic solvent Substances 0.000 claims abstract description 56
- -1 diisocyanate compound Chemical class 0.000 claims abstract description 38
- 229920000642 polymer Polymers 0.000 claims abstract description 35
- 239000000463 material Substances 0.000 claims abstract description 33
- 229920005862 polyol Polymers 0.000 claims abstract description 30
- 150000003077 polyols Chemical class 0.000 claims abstract description 30
- 238000006243 chemical reaction Methods 0.000 claims abstract description 22
- 238000012644 addition polymerization Methods 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims description 37
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 33
- 229940126062 Compound A Drugs 0.000 claims description 31
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims description 31
- 150000001875 compounds Chemical class 0.000 claims description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 30
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 29
- 239000011148 porous material Substances 0.000 claims description 29
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 24
- 239000003054 catalyst Substances 0.000 claims description 24
- 239000003381 stabilizer Substances 0.000 claims description 24
- 238000003756 stirring Methods 0.000 claims description 22
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 20
- 238000000855 fermentation Methods 0.000 claims description 14
- 230000004151 fermentation Effects 0.000 claims description 14
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- 229920002545 silicone oil Polymers 0.000 claims description 11
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims description 9
- YEJRWHAVMIAJKC-UHFFFAOYSA-N 4-Butyrolactone Chemical compound O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 8
- 239000012153 distilled water Substances 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 230000035484 reaction time Effects 0.000 claims description 8
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 claims description 8
- SVONRAPFKPVNKG-UHFFFAOYSA-N 2-ethoxyethyl acetate Chemical compound CCOCCOC(C)=O SVONRAPFKPVNKG-UHFFFAOYSA-N 0.000 claims description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- 229920002678 cellulose Polymers 0.000 claims description 6
- 239000001913 cellulose Substances 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 6
- 239000012528 membrane Substances 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- 230000008439 repair process Effects 0.000 claims description 6
- UPMLOUAZCHDJJD-UHFFFAOYSA-N 4,4'-Diphenylmethane Diisocyanate Chemical compound C1=CC(N=C=O)=CC=C1CC1=CC=C(N=C=O)C=C1 UPMLOUAZCHDJJD-UHFFFAOYSA-N 0.000 claims description 5
- 235000002837 Acetobacter xylinum Nutrition 0.000 claims description 5
- 239000005058 Isophorone diisocyanate Substances 0.000 claims description 5
- 241001136169 Komagataeibacter xylinus Species 0.000 claims description 5
- 239000005062 Polybutadiene Substances 0.000 claims description 5
- NIMLQBUJDJZYEJ-UHFFFAOYSA-N isophorone diisocyanate Chemical compound CC1(C)CC(N=C=O)CC(C)(CN=C=O)C1 NIMLQBUJDJZYEJ-UHFFFAOYSA-N 0.000 claims description 5
- 229920002857 polybutadiene Polymers 0.000 claims description 5
- KSBAEPSJVUENNK-UHFFFAOYSA-L tin(ii) 2-ethylhexanoate Chemical compound [Sn+2].CCCCC(CC)C([O-])=O.CCCCC(CC)C([O-])=O KSBAEPSJVUENNK-UHFFFAOYSA-L 0.000 claims description 5
- DVKJHBMWWAPEIU-UHFFFAOYSA-N toluene 2,4-diisocyanate Chemical compound CC1=CC=C(N=C=O)C=C1N=C=O DVKJHBMWWAPEIU-UHFFFAOYSA-N 0.000 claims description 5
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 claims description 4
- 241000589516 Pseudomonas Species 0.000 claims description 4
- UKLDJPRMSDWDSL-UHFFFAOYSA-L [dibutyl(dodecanoyloxy)stannyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)O[Sn](CCCC)(CCCC)OC(=O)CCCCCCCCCCC UKLDJPRMSDWDSL-UHFFFAOYSA-L 0.000 claims description 4
- 229930188620 butyrolactone Natural products 0.000 claims description 4
- 229960002887 deanol Drugs 0.000 claims description 4
- 239000012975 dibutyltin dilaurate Substances 0.000 claims description 4
- 239000012972 dimethylethanolamine Substances 0.000 claims description 4
- 229920001451 polypropylene glycol Polymers 0.000 claims description 4
- 229920001296 polysiloxane Polymers 0.000 claims description 4
- 238000002791 soaking Methods 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- 241000590020 Achromobacter Species 0.000 claims description 3
- 241000588986 Alcaligenes Species 0.000 claims description 3
- 241000589151 Azotobacter Species 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 241000589180 Rhizobium Species 0.000 claims description 3
- GLSRFBDXBWZNLH-UHFFFAOYSA-L disodium;2-chloroacetate;2-(4,5-dihydroimidazol-1-yl)ethanol;hydroxide Chemical compound [OH-].[Na+].[Na+].[O-]C(=O)CCl.OCCN1CCN=C1 GLSRFBDXBWZNLH-UHFFFAOYSA-L 0.000 claims description 3
- 229940096501 sodium cocoamphoacetate Drugs 0.000 claims description 3
- 108010077805 Bacterial Proteins Proteins 0.000 claims description 2
- 229940079881 disodium lauroamphodiacetate Drugs 0.000 claims description 2
- QKQCPXJIOJLHAL-UHFFFAOYSA-L disodium;2-[2-(carboxylatomethoxy)ethyl-[2-(dodecanoylamino)ethyl]amino]acetate Chemical compound [Na+].[Na+].CCCCCCCCCCCC(=O)NCCN(CC([O-])=O)CCOCC([O-])=O QKQCPXJIOJLHAL-UHFFFAOYSA-L 0.000 claims description 2
- 239000012258 stirred mixture Substances 0.000 claims description 2
- 239000002121 nanofiber Substances 0.000 abstract description 15
- 239000000126 substance Substances 0.000 abstract description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract description 8
- 238000010521 absorption reaction Methods 0.000 abstract description 6
- OMOVVBIIQSXZSZ-UHFFFAOYSA-N [6-(4-acetyloxy-5,9a-dimethyl-2,7-dioxo-4,5a,6,9-tetrahydro-3h-pyrano[3,4-b]oxepin-5-yl)-5-formyloxy-3-(furan-3-yl)-3a-methyl-7-methylidene-1a,2,3,4,5,6-hexahydroindeno[1,7a-b]oxiren-4-yl] 2-hydroxy-3-methylpentanoate Chemical compound CC12C(OC(=O)C(O)C(C)CC)C(OC=O)C(C3(C)C(CC(=O)OC4(C)COC(=O)CC43)OC(C)=O)C(=C)C32OC3CC1C=1C=COC=1 OMOVVBIIQSXZSZ-UHFFFAOYSA-N 0.000 abstract 1
- 230000002349 favourable effect Effects 0.000 abstract 1
- 206010052428 Wound Diseases 0.000 description 24
- 208000027418 Wounds and injury Diseases 0.000 description 24
- 230000005540 biological transmission Effects 0.000 description 14
- 230000029663 wound healing Effects 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 9
- 210000000416 exudates and transudate Anatomy 0.000 description 9
- 238000012360 testing method Methods 0.000 description 8
- 230000018044 dehydration Effects 0.000 description 6
- 238000006297 dehydration reaction Methods 0.000 description 6
- 239000000017 hydrogel Substances 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- IQPQWNKOIGAROB-UHFFFAOYSA-N isocyanate group Chemical group [N-]=C=O IQPQWNKOIGAROB-UHFFFAOYSA-N 0.000 description 5
- 230000007935 neutral effect Effects 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 238000012925 biological evaluation Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 125000005442 diisocyanate group Chemical group 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- HXDLWJWIAHWIKI-UHFFFAOYSA-N 2-hydroxyethyl acetate Chemical compound CC(=O)OCCO HXDLWJWIAHWIKI-UHFFFAOYSA-N 0.000 description 2
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 2
- 241000192023 Sarcina Species 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- 206010072170 Skin wound Diseases 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000011056 performance test Methods 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000002352 surface water Substances 0.000 description 2
- 241000700198 Cavia Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 229920003043 Cellulose fiber Polymers 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical group [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 206010070835 Skin sensitisation Diseases 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000007665 chronic toxicity Effects 0.000 description 1
- 231100000160 chronic toxicity Toxicity 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920006264 polyurethane film Polymers 0.000 description 1
- 239000003361 porogen Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 231100000370 skin sensitisation Toxicity 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N urethane group Chemical group NC(=O)OCC JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/40—High-molecular-weight compounds
- C08G18/48—Polyethers
- C08G18/4833—Polyethers containing oxyethylene units
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L75/00—Compositions of polyureas or polyurethanes; Compositions of derivatives of such polymers
- C08L75/04—Polyurethanes
- C08L75/08—Polyurethanes from polyethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/225—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
- A61L27/48—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with macromolecular fillers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B15/00—Preparation of other cellulose derivatives or modified cellulose, e.g. complexes
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/08—Processes
- C08G18/16—Catalysts
- C08G18/18—Catalysts containing secondary or tertiary amines or salts thereof
- C08G18/20—Heterocyclic amines; Salts thereof
- C08G18/2045—Heterocyclic amines; Salts thereof containing condensed heterocyclic rings
- C08G18/2063—Heterocyclic amines; Salts thereof containing condensed heterocyclic rings having two nitrogen atoms in the condensed ring system
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/30—Low-molecular-weight compounds
- C08G18/32—Polyhydroxy compounds; Polyamines; Hydroxyamines
- C08G18/3203—Polyhydroxy compounds
- C08G18/3206—Polyhydroxy compounds aliphatic
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/40—High-molecular-weight compounds
- C08G18/4009—Two or more macromolecular compounds not provided for in one single group of groups C08G18/42 - C08G18/64
- C08G18/4081—Mixtures of compounds of group C08G18/64 with other macromolecular compounds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/40—High-molecular-weight compounds
- C08G18/48—Polyethers
- C08G18/4804—Two or more polyethers of different physical or chemical nature
- C08G18/4808—Mixtures of two or more polyetherdiols
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/40—High-molecular-weight compounds
- C08G18/48—Polyethers
- C08G18/4825—Polyethers containing two hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/40—High-molecular-weight compounds
- C08G18/64—Macromolecular compounds not provided for by groups C08G18/42 - C08G18/63
- C08G18/6484—Polysaccharides and derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/65—Low-molecular-weight compounds having active hydrogen with high-molecular-weight compounds having active hydrogen
- C08G18/66—Compounds of groups C08G18/42, C08G18/48, or C08G18/52
- C08G18/6666—Compounds of group C08G18/48 or C08G18/52
- C08G18/667—Compounds of group C08G18/48 or C08G18/52 with compounds of group C08G18/32 or polyamines of C08G18/38
- C08G18/6674—Compounds of group C08G18/48 or C08G18/52 with compounds of group C08G18/32 or polyamines of C08G18/38 with compounds of group C08G18/3203
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/70—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the isocyanates or isothiocyanates used
- C08G18/72—Polyisocyanates or polyisothiocyanates
- C08G18/721—Two or more polyisocyanates not provided for in one single group C08G18/73 - C08G18/80
- C08G18/724—Combination of aromatic polyisocyanates with (cyclo)aliphatic polyisocyanates
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/70—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the isocyanates or isothiocyanates used
- C08G18/72—Polyisocyanates or polyisothiocyanates
- C08G18/74—Polyisocyanates or polyisothiocyanates cyclic
- C08G18/75—Polyisocyanates or polyisothiocyanates cyclic cycloaliphatic
- C08G18/751—Polyisocyanates or polyisothiocyanates cyclic cycloaliphatic containing only one cycloaliphatic ring
- C08G18/752—Polyisocyanates or polyisothiocyanates cyclic cycloaliphatic containing only one cycloaliphatic ring containing at least one isocyanate or isothiocyanate group linked to the cycloaliphatic ring by means of an aliphatic group
- C08G18/753—Polyisocyanates or polyisothiocyanates cyclic cycloaliphatic containing only one cycloaliphatic ring containing at least one isocyanate or isothiocyanate group linked to the cycloaliphatic ring by means of an aliphatic group containing one isocyanate or isothiocyanate group linked to the cycloaliphatic ring by means of an aliphatic group having a primary carbon atom next to the isocyanate or isothiocyanate group
- C08G18/755—Polyisocyanates or polyisothiocyanates cyclic cycloaliphatic containing only one cycloaliphatic ring containing at least one isocyanate or isothiocyanate group linked to the cycloaliphatic ring by means of an aliphatic group containing one isocyanate or isothiocyanate group linked to the cycloaliphatic ring by means of an aliphatic group having a primary carbon atom next to the isocyanate or isothiocyanate group and at least one isocyanate or isothiocyanate group linked to a secondary carbon atom of the cycloaliphatic ring, e.g. isophorone diisocyanate
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/70—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the isocyanates or isothiocyanates used
- C08G18/72—Polyisocyanates or polyisothiocyanates
- C08G18/74—Polyisocyanates or polyisothiocyanates cyclic
- C08G18/76—Polyisocyanates or polyisothiocyanates cyclic aromatic
- C08G18/7614—Polyisocyanates or polyisothiocyanates cyclic aromatic containing only one aromatic ring
- C08G18/7621—Polyisocyanates or polyisothiocyanates cyclic aromatic containing only one aromatic ring being toluene diisocyanate including isomer mixtures
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/70—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the isocyanates or isothiocyanates used
- C08G18/72—Polyisocyanates or polyisothiocyanates
- C08G18/74—Polyisocyanates or polyisothiocyanates cyclic
- C08G18/76—Polyisocyanates or polyisothiocyanates cyclic aromatic
- C08G18/7657—Polyisocyanates or polyisothiocyanates cyclic aromatic containing two or more aromatic rings
- C08G18/7664—Polyisocyanates or polyisothiocyanates cyclic aromatic containing two or more aromatic rings containing alkylene polyphenyl groups
- C08G18/7671—Polyisocyanates or polyisothiocyanates cyclic aromatic containing two or more aromatic rings containing alkylene polyphenyl groups containing only one alkylene bisphenyl group
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L1/00—Compositions of cellulose, modified cellulose or cellulose derivatives
- C08L1/02—Cellulose; Modified cellulose
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G2110/00—Foam properties
- C08G2110/0083—Foam properties prepared using water as the sole blowing agent
Definitions
- the invention belongs to the technical field of skin repair, and relates to a bacterial cellulose-polyurethane composite material with a gradient structure, and a preparation method and application thereof.
- the wound healing process is a continuous dynamic process, which is a process of interaction between cells and cells, cells and cell matrix, and soluble media.
- wound dressings are mainly used.
- wet therapy high-performance wet dressings with hygroscopic function are gaining more and more attention in the field of medical and health in the world.
- the commonly used dressings in clinic can be divided into bacterial cellulose dressings and polyurethane dressings according to different materials.
- Bacterial cellulose is a polymer compound connected by glucose with ⁇ -1,4-glycoside chains. As an excellent biological material, it has unique physical and chemical properties: Bacterial cellulose has a natural three-dimensional nano network structure ; High tensile strength and elastic modulus; high hydrophilicity, good air permeability, water absorption, water permeability, extraordinary water holding capacity and high wet strength. In addition, a large number of studies have shown that bacterial cellulose has good in vivo and in vitro biocompatibility and biodegradability, which makes the bacterial cellulose itself can be used in the field of biomedicine. The use of simple bacterial cellulose hydrogel as dressing has been reported abroad, and it has been industrialized for clinical use.
- Polyurethane is a general term for polymers containing urethane groups (-NHCOO-) on the main chain of the polymer structure.
- the soft and hard segments in its molecular structure belong to a thermodynamically incompatible system, and there are differences in polarity, which can cause microphase separation, so it has good biocompatibility and anticoagulant properties.
- a large number of animal experiments and acute and chronic toxicity experiments have confirmed that medical polyurethane materials have good blood compatibility and tissue compatibility with humans, are non-toxic and non-distorting, have no local allergic reactions, and have good toughness, solvent resistance, and hydrolysis resistance. It is considered to be one of the most valuable biomedical synthetic materials because of its properties and antibacterial properties, wear resistance, easy processing and molding, and controllable performance.
- An object of the present invention is to provide a bacterial cellulose-polyurethane composite material with a gradient structure; another object of the present invention is to provide a preparation method of the bacterial cellulose-polyurethane composite material with a gradient structure; another aspect of the present invention The purpose is to provide the application of the bacterial cellulose-polyurethane composite material with a gradient structure in human body repair materials, intelligent drug slow-release materials and tissue engineering materials.
- the bacterial cellulose microfibers are subjected to organic solvent exchange treatment to obtain composite A and composite B of bacterial cellulose microfibers of different concentrations;
- the compound A is calculated by weight as 100% by weight, including 30-50% by weight of completely dehydrated bacterial cellulose microfibers and the balance of organic solvent
- the compound B is calculated by weight by 100% by weight, including 15-30% by weight of partially dehydrated bacterial cellulose microfibers and the balance of organic solvent
- the partially dehydrated bacterial cellulose microfibers contain 5-10% by weight (based on the weight of the compound B) of water
- the compound A and compound B are mixed at a volume ratio of 1:(2 ⁇ 5), polymer polyol and diisocyanate compound are added under oil bath conditions for addition polymerization reaction, and the reaction obtains the bacterial cellulose composite polyurethane foam. Polymer; After curing it, a bacterial cellulose-polyurethane composite material is obtained;
- the weight ratio of the polymer polyol and the diisocyanate compound is 1: (0.1 to 0.2); the polymer polyol accounts for 20% to 20% of the total weight of the composite A and the composite B 60%.
- the bacterial cellulose-polyurethane composite material prepared by the present invention has a gradient double-layer structure with different pore diameters, one layer is a macroporous layer (mainly containing more compound B), and the other layer is a microporous layer (mainly containing More composite A), the bacterial cellulose-polyurethane composite is an organic whole composed of a macroporous layer and a microporous layer.
- the upper layer is a microporous layer that can prevent bacteria from water and prevent water vapor transmission during use.
- the lower layer is the macroporous layer, which can maintain the moist microenvironment of the wound, control wound exudate, and promote wound healing.
- the above preparation method preferably, it further includes the process of purifying and homogenizing the bacterial cellulose obtained by fermentation of the strain to obtain bacterial cellulose microfiber; the strain includes Acetobacter xylinum, Rhizobium, and Sarcina , Pseudomonas, Achromobacter, Alcaligenes, Aerobacter and Azotobacter in combination of one or more.
- the above preparation method preferably, it further includes a process of purifying and homogenizing bacterial cellulose obtained by fermentation of the strain to obtain bacterial cellulose microfibers; wherein, the method of purifying bacterial cellulose includes:
- the method for homogenizing bacterial cellulose is:
- the organic solvent exchange treatment method is:
- the conditions for the addition polymerization reaction are: a constant temperature oil bath at 70°C to 80°C, and the reaction time is 60 to 90 minutes.
- the amount ratio of the diisocyanate compound and water is (20-40): (2-5).
- the diisocyanate compound includes one or a combination of toluene diisocyanate, diphenylmethane diisocyanate, and isophorone diisocyanate.
- the curing aid includes a catalyst, a pore opening agent and a stabilizer
- the amount of the catalyst is 0.3 to 1.5% by weight of the amount of the bacterial cellulose composite polyurethane foam prepolymer; the amount of the cell opener is the amount of the bacterial cellulose composite polyurethane foam prepolymer The amount of the stabilizer is 0.1 to 0.5% by weight of the amount of the bacterial cellulose composite polyurethane foam prepolymer.
- the use of the above curing aids in the present invention facilitates the conversion of polyurethane foam materials from liquid to solid, and at the same time, the residual isocyanate groups in the polyurethane interact with the hydroxyl groups on the surface of the bacterial cellulose nanofibers to form urethane bonds.
- the bacterial cellulose nanofibers and polyurethane foam materials are effectively combined by chemical bonding.
- the curing is to place the uniformly mixed and stirred mixture in a mold and let it stand for 2-7 days at room temperature.
- the present invention also provides a bacterial cellulose-polyurethane composite material, which includes at least two layers of a macroporous layer and a microporous layer.
- the pore size of the macroporous layer is 100-500 ⁇ m, and the porosity is 70%-90%.
- the thickness is 0.5 to 1 cm; the pore size of the microporous layer is 10 to 80 ⁇ m, the porosity is 60% to 80%, and the thickness is 0.1 to 0.3 cm.
- the bacterial cellulose-polyurethane composite material of the present invention is prepared by the above-mentioned preparation method.
- the mass ratio of the bacterial cellulose microfibers in the composite material is 20-40 wt%, and the hydroxyl groups on the surface of the nanofibers are chemically bonded with the residual isocyanate groups in the polyurethane.
- the bacterial cellulose-polyurethane composite material prepared by the present invention has a gradient double-layer structure with different pore diameters, one layer is a macroporous layer, and the other layer is a microporous layer.
- the bacterial cellulose-polyurethane composite material is an organic whole composed of a macroporous layer and a microporous layer.
- the upper layer is a microporous layer that can prevent bacteria and water vapor and control the water vapor transmission rate; the lower layer is a macroporous layer. Maintain the moist microenvironment of the wound, control wound exudate, and promote wound healing.
- the present invention also provides the application of the bacterial cellulose-polyurethane composite material in human body repair materials, intelligent drug slow-release materials and tissue engineering materials.
- the present invention adopts the composite of bacterial cellulose nanofiber microfiber and polyurethane foam material to significantly improve the mechanical properties of the composite material; a large number of hydroxyl groups on the surface of the bacterial cellulose nanofiber effectively strengthen the hydrophilic performance and water absorption capacity of the composite material; at the same time; The good tissue affinity of bacterial cellulose can improve the biocompatibility of polyurethane materials;
- the residual isocyanate groups in the polyurethane reaction interact with the hydroxyl groups on the surface of the bacterial cellulose nanofibers to effectively combine the bacterial cellulose nanofibers with the polyurethane foam matrix by means of chemical bonding;
- Step one immerse the bacterial cellulose obtained by the fermentation and culture of Acetobacter xylinum in a 4% NaOH aqueous solution, heat at 100°C for 6 hours, and then repeatedly rinse with distilled water until it is neutral; then use high-speed dispersion
- the purified bacterial cellulose sample was homogenized for 10 minutes at a rotation speed of 25000 rpm and a bacterial cellulose microfiber with a length of 0.1 ⁇ m and a diameter of 50 nm was obtained.
- the bacterial cellulose-polyurethane composite material has a gradient double-layer structure with different pore diameters, one layer is a macroporous layer, the macropore pore diameter is 100 ⁇ m, the porosity is 70%, and the thickness is 0.5cm; the other layer is a microporous layer with pore diameters. It is 10 ⁇ m, the porosity is 60%, and the thickness is 0.1 cm.
- the bacterial cellulose-polyurethane composite material is an organic whole composed of a macroporous layer and a microporous layer. During use, the upper layer is a microporous layer that can prevent bacteria and water vapor and control the water vapor transmission rate; the lower layer is a macroporous layer. Maintain the moist microenvironment of the wound, control wound exudate, and promote wound healing.
- the added curing aid includes a catalyst, a cell opener and a stabilizer;
- the catalyst is dibutyltin dilaurate, and the amount is 0.9wt% of the amount of the bacterial cellulose composite polyurethane foam prepolymer;
- the cell opener is polybutadiene two
- the amount of alcohol is 0.5wt% of the amount of the bacterial cellulose composite polyurethane foam prepolymer;
- the stabilizer is sodium cinnamoyl amphoteric acetate, and the amount is 0.3wt% of the amount of bacterial cellulose composite polyurethane foam prepolymer.
- Step 1 Soak the bacterial cellulose obtained by the mixed fermentation culture of Alcaligenes, Aerobacter and Azotobacter in a 7% by mass NaOH aqueous solution, heat it at 70°C for 4 hours, and then use distilled water Rinse repeatedly until it is neutral; then, homogenize the purified bacterial cellulose sample for 8 minutes with a high-speed disperser at a rotation speed of 15000 rpm to obtain bacterial cellulose microfibers with a length of 6 ⁇ m and a diameter of 80 nm.
- Step 2 Soak the homogenized bacterial cellulose microfibers in absolute ethanol for 10 hours to ensure complete dehydration of the bacterial cellulose microfibers, and then soak the dehydrated bacterial cellulose microfibers in organic solvents such as acetic acid and acetone After 36 hours, compound A was prepared.
- the compound A was 100wt% by weight, including 30wt% of bacterial cellulose microfiber and the balance of organic solvent (the balance of organic solvent included residual anhydrous Ethanol, acetic acid and acetone).
- Step 3 Mix compound A and compound B at a volume ratio of 1:2, add polymer polyol and a small amount of diisocyanate compound for addition polymerization under the condition of a constant temperature oil bath at 80°C, and stir.
- the reaction time is 90 minutes, and the bacterial cellulose composite polyurethane foam prepolymer is obtained by the reaction.
- the added amount of polymer polyol is 40% of the total mass of compound A and compound B after mixing.
- Biocompatibility evaluation Intracellular toxicity test is carried out in accordance with GB/T 16886-5 "Biological Evaluation of Medical Devices Part 5: In Vitro Cytotoxicity Test”; Guinea pig delayed contact sensitization test is in accordance with GB/T 16886-10 " Biological Evaluation of Medical Devices Part 10: Stimulus and Delayed Hypersensitivity Test” for testing, using the maximum test Magnusson and Kligman method. The skin irritation test is tested in accordance with GB/T 16886-10 "Biological Evaluation of Medical Devices Part 10: Irritation and Delayed Hypersensitivity Test".
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Composite Materials (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Materials For Medical Uses (AREA)
- Polyurethanes Or Polyureas (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
一种细菌纤维素-聚氨酯复合材料及其制备方法和应用,制备方法包括:将细菌纤维素微纤进行有机溶剂交换处理,获得不同浓度的细菌纤维素微纤的复合物A和复合物B;于油浴条件下加入聚合物多元醇和二异氰酸酯类化合物进行加聚反应,反应得到细菌纤维素复合聚氨酯泡沫预聚体;然后进行固化得到该细菌纤维素-聚氨酯复合材料。采用细菌纤维素微纤与聚氨酯泡沫材料复合,显著提高了复合材料的力学性能;细菌纤维素纳米纤维表面大量羟基有效加强了复合材料的亲水性能及吸水能力;同时细菌纤维素良好的组织亲和能力可以改善聚氨酯材料的生物相容性。
Description
本发明属于皮肤修复技术领域,涉及一种具有梯度结构的细菌纤维素-聚氨酯复合材料及其制备方法和应用。
伤口的愈合过程是一个连续的动态过程,是细胞与细胞、细胞与细胞基质以及与可溶性介质间相互作用的过程。临床上伤口的治愈以伤口敷料使用为主,随着“湿法疗法”理论和实践得到普及,具有吸湿功能的高性能湿性敷料在在世界医疗卫生领域得到日益重视。
目前临床上常用的敷料按材质的不同可分为细菌纤维素类敷料、聚氨酯敷料等。
细菌纤维素是由葡萄糖以β-1,4-糖苷链连接而成的高分子化合物,作为一种优良的生物材料,具有其独特的物理、化学性能:细菌纤维素具有天然的三维纳米网络结构;高抗张强度和弹性模量;高亲水性,良好的透气、吸水、透水性能,非凡的持水性和高湿强度。另外,大量研究表明细菌纤维素具有良好的体内、体外生物相容性和生物可降解性,这使得细菌纤维素本身可以应用于生物医用领域。国外采用单纯的细菌纤维素水凝胶作为敷料已有报道,并且已经产业化用于临床。因此,以细菌纤维素水凝胶作为敷料的基体材料,利用细菌纤维素本身的吸水性能,可以在保证生物安全性的基础上持续有效地吸收伤口渗出液及代谢产物。细菌纤维素水凝胶用于伤口敷料领域有很好的发展前景,它为伤口提供了湿润的环境以促进伤口更好地愈合。但是细菌纤维素水凝胶本身的三维纳米网络结构缺少良好的防水阻菌性能,外界的微生物及水分能够透过其纳米网络渗入到伤口。同时,细菌纤维素水凝胶敷料具有较大的水蒸气透过率,在使用过程中其内部的水分较易失去。这些问题都制约了细菌纤维素水凝胶敷料的应用。
聚氨酯是在高分子结构主链上含有氨基甲酸酯基团(-NHCOO-)的聚合物总称。其分子结构中的软硬段属热力学不相容体系,存在极性差异,可引起微相分离,因此具备良好的生物相容性、抗凝血性。大量动物实验和急慢性毒性实验证实,医用聚氨酯材料与人体血液相容性和组织相容性好,无毒无致畸变作用,对局部无过敏反应,有良好的韧性、耐溶剂性、耐水解性及抗菌性,并且耐磨损,容易加工成型,性能可控,所以被认为是最具价值的生物医学合成材料之一。1、采用聚氨酯薄膜制备的敷料产品能够保持 创面的湿润,控制水蒸气透过速率,并抵御微生物和外界水分的侵入。2、聚氨酯泡沫材料具有较好的生物相容性、亲水性和柔软性,可吸收体液或血液,避免积液的形成,具有很好的柔软性服帖性,利于和组织较好地贴和,减少不适和疼痛,特有的孔状结构还可以根据需要加载和释放药物,与组织不粘连,易于揭取更换。如聚氨酯泡沫敷料既可以用于保持创面湿润,又可允许气体通过,促进创面愈合。但是聚氨酯泡沫在实际应用中其生物相容性、力学性能和亲水性能有待于加强,尤其是在人体修复材料、智能药物缓释材料和组织工程材料的应用方面。
因此,当前的皮肤创伤敷料产品有待进一步改进。
发明内容
本发明的一个目的在于提供一种具有梯度结构的细菌纤维素-聚氨酯复合材料;本发明的另一目的在于提供该具有梯度结构的细菌纤维素-聚氨酯复合材料的制备方法;本发明的再一目的在于提供该具有梯度结构的细菌纤维素-聚氨酯复合材料在人体修复材料、智能药物缓释材料和组织工程材料中的应用。
本发明的目的通过以下技术方案得以实现:
一方面,本发明提供一种细菌纤维素-聚氨酯复合材料的制备方法,其包括以下步骤:
将细菌纤维素微纤进行有机溶剂交换处理,获得不同浓度的细菌纤维素微纤的复合物A和复合物B;
其中,所述复合物A以重量份为100wt%计,包括30~50wt%的完全脱水的细菌纤维素微纤和余量的有机溶剂;所述复合物B以重量份为100wt%计,包括15~30wt%的部分脱水的细菌纤维素微纤和余量的有机溶剂;其中,部分脱水的细菌纤维素微纤中含有5~10wt%(以复合物B的重量份计)的水;
将复合物A和复合物B以体积比为1:(2~5)进行混合,于油浴条件下加入聚合物多元醇和二异氰酸酯类化合物进行加聚反应,反应得到细菌纤维素复合聚氨酯泡沫预聚体;将其固化后得到细菌纤维素-聚氨酯复合材料;
其中,所述聚合物多元醇和所述二异氰酸酯类化合物的重量比为1:(0.1~0.2);所述聚合物多元醇占所述复合物A和所述复合物B总重量的20%~60%。
本发明创造性的将细菌纤维素和聚氨酯联合制备复合材料,采用细菌纤维素的纳米纤维微纤均匀分布在聚氨酯材料的内部,增强聚氨酯泡沫材料,通过聚氨酯反应中残留 的异氰酸酯基团与细菌纤维素纳米纤维表面的羟基基团相互作用,以化学键合的方式使细菌纤维素纳米纤维与聚氨酯泡沫基体有效结合,使得该复合材料的力学性能得到了显著提高;细菌纤维素纳米纤维表面大量羟基有效提高了复合材料的亲水性能及吸水能力;同时细菌纤维素良好的组织亲和能力可以改善聚氨酯材料的生物相容性,发挥两种材料的优势,得到的一款理想的皮肤创伤敷料产品,使其在生物医用领域具有巨大的应用前景。
本发明中,复合物A是细菌纤维素微纤完全脱水后与有机溶剂的混合物,复合物B是细菌纤维素微纤脱去表面游离水,仍含有少量结合水的微纤与有机溶剂的混合物。本发明采取溶剂交换的方法,在不破坏细菌纤维素纳米纤维表面羟基的基础上去除部分水分子;少量的结合水能够与异氰酸酯基团反应生成二氧化碳(2RNCO+H
2O→RNHCONHR+CO
2↑),具有致孔剂的功能。在制备过程中,由于纤维素微纤不同含水量的比重不同,复合物A与复合物B按照体积比1:(2~5)进行调配后,会在沉降过程中自动分层,含水量的不同会使致孔的二氧化碳气体量不同,从而形成不同的孔径分布。因此,本发明制备的细菌纤维素-聚氨酯复合材料为具有不同孔径的梯度双层结构,一层为大孔层(主要包含较多的复合物B),另一层为微孔层(主要包含较多的复合物A),该细菌纤维素-聚氨酯复合材料是由大孔层与微孔层构成的有机整体,在使用过程中上层为微孔层能够防水阻菌,并控制水蒸气透过率;下层为大孔层能够保持伤口湿性微环境、控制伤口渗出液、促进伤口愈合。
上述的制备方法中,优选地,还包括将菌株发酵得到的细菌纤维素进行纯化、均质处理得到细菌纤维素微纤的过程;所述菌株包括木醋杆菌、根瘤菌属、八叠球菌属、假单胞菌属、无色杆菌属、产碱菌属、气杆菌属和固氮菌属中的一种或多种的组合。
本发明中,采取上述菌株进行发酵的方法为本领域常规方法,发酵培养基为本领域生产细菌纤维素常规培养基,发酵时间一般为3~7天,发酵温度为30℃~37℃。
上述的制备方法中,优选地,还包括将菌株发酵得到的细菌纤维素进行纯化、均质处理得到细菌纤维素微纤的过程;其中,对细菌纤维素进行纯化的方法包括:
于70℃~100℃的温度下,将细菌纤维素在质量百分含量为4%~8%的氢氧化钠水溶液中洗涤4~6h,再用蒸馏水反复冲洗至中性,以除去细菌纤维素上的菌体蛋白和粘附在纤维素膜上的残余培养基,获得纯化后的细菌纤维素。
上述的制备方法中,优选地,对细菌纤维素进行均质处理的方法为:
采用高速分散机于5000~25000rpm的转速下,对纯化后的细菌纤维素均质5~10min, 得到细菌纤维素微纤。
上述的制备方法中,优选地,所述细菌纤维素微纤的长度为0.1~10μm,直径为50~100nm。该细菌纤维素微纤是由多根纳米级的细菌纤维素纤维通过分子间氢键合股形成的纤维束。
上述的制备方法中,优选地,所述有机溶剂交换处理的方法为:
将细菌纤维素微纤浸泡于无水乙醇中,通过控制浸泡时间8~12h获得完全脱水后的细菌纤维素微纤和控制浸泡时间3~6h获得部分脱水后的细菌纤维素微纤;
将完全脱水后的细菌纤维素微纤浸泡于有机溶剂中48~72h,获得复合物A;
将部分脱水后的细菌纤维素微纤浸泡于有机溶剂中12~48h,获得复合物B。
本发明中,对细菌纤维素微纤表面游离水与内部结合水的控制,通过将细菌纤维素微纤浸泡在无水乙醇中,随着无水乙醇浸泡时间的增长,无水乙醇会首先将细菌纤维素微纤表面的游离水析出,然后将细菌纤维素微纤内部(组成微纤的纳米纤维之间的)的结合水析出。最终得到的复合物A是细菌纤维素微纤完全脱水后与有机溶剂的混合物,复合物B是细菌纤维素微纤脱去表面游离水,仍含有少量结合水的微纤与有机溶剂的混合物。
上述的制备方法中,优选地,所述有机溶剂包括乙基乙二醇乙酸酯、乙酸乙酯、丁内酯、乙酸和丙酮中的一种或多种的组合。
本发明采用的有机溶剂能够降低细菌纤维素中的纳米级纤维素纤维与水分子之间的相互作用,避免游离水的存在,提高聚氨酯泡沫生产过程中的反应效率,同时加强细菌纤维素纳米纤维素纤维与聚氨酯之间的界面作用。
上述的制备方法中,优选地,进行加聚反应的条件为:70℃~80℃下恒温油浴,反应时间为60~90min。
上述的制备方法中,优选地,所述聚合物多元醇包括聚乙二醇、聚环氧丙烷、丙二醇和一缩二乙二醇中的一种或多种的组合。
上述的制备方法中,优选地,对所述细菌纤维素复合聚氨酯泡沫预聚体进行固化的方法为:
向细菌纤维素复合聚氨酯泡沫预聚体中加入固化助剂并搅拌均匀,然后加入二异氰酸酯类化合物和水并搅拌均匀得到混合物,然后固化得到细菌纤维素-聚氨酯复合材料。
上述的制备方法中,优选地,所述固化助剂的用量为细菌纤维素复合聚氨酯泡沫预聚体用量的0.5~2.6wt%。
上述的制备方法中,优选地,所述二异氰酸酯类化合物和水的用量比为(20~40):(2~5)。
上述的制备方法中,优选地,固化中,所述二异氰酸酯类化合物的用量为所述聚合物多元醇用量的20%~50%。
上述的制备方法中,优选地,所述二异氰酸酯类化合物包括甲苯二异氰酸酯、二苯基甲烷二异氰酸酯和异佛尔酮二异氰酸酯中的一种或多种的组合。
本发明中采用聚合物多元醇与二异氰酸酯分别作用聚氨酯材料的软段结构和硬段结构,生成的聚醚型聚氨酯具有优异的力学性能和良好的生物相容性。
上述的制备方法中,优选地,所述固化助剂包括催化剂、开孔剂和稳定剂;
所述催化剂包括三亚乙基二胺、二甲基乙醇胺、二月桂酸二丁基锡和辛酸亚锡中的一种或多种的组合;
所述开孔剂包括开孔硅油、硅油6070和聚丁二烯二醇中的一种或多种的组合;
所述稳定剂包括有机硅表面活性剂、椰油酰两性基乙酸钠、桂酰两性基乙酸钠和月桂酰两性基二乙酸二钠中的一种或多种的组合。
上述的制备方法中,优选地,所述催化剂的用量为细菌纤维素复合聚氨酯泡沫预聚体用量的0.3~1.5wt%;所述开孔剂的用量为细菌纤维素复合聚氨酯泡沫预聚体用量的0.1~1wt%;所述稳定剂的用量为细菌纤维素复合聚氨酯泡沫预聚体用量的0.1~0.5wt%。
本发明中采用上述固化助剂有利于聚氨酯泡沫材料由液态向固态的转化,同时也伴随聚氨酯中残留的异氰酸酯基团与细菌纤维素纳米纤维表面的羟基基团相互作用生成氨基甲酸酯键,以化学键合的方式将细菌纤维素纳米纤维与聚氨酯泡沫材料有效结合。
上述的制备方法中,优选地,所述固化是将混合搅拌均匀的混合物置于模具中,于室温条件下静置2~7d。
另一方面,本发明还提供一种细菌纤维素-聚氨酯复合材料,其包括大孔层和微孔层至少两层结构,大孔层的孔径为100~500μm,孔隙率为70%~90%,厚度为0.5~1cm;微孔层的孔径为10~80μm,孔隙率为60%~80%;厚度为0.1~0.3cm。
本发明的细菌纤维素-聚氨酯复合材料是通过上述制备方法制备获得的。
上述的细菌纤维素-聚氨酯复合材料中,所述细菌纤维素微纤在复合材料中的质量占比为20~40wt%,且纳米纤维表面的羟基与聚氨酯中残留的异氰酸酯基团存在化学键合。
本发明制备获得的细菌纤维素-聚氨酯复合材料具有不同孔径的梯度双层结构,一 层为大孔层,另一层为微孔层。该细菌纤维素-聚氨酯复合材料是由大孔层与微孔层构成的有机整体,在使用过程中上层为微孔层能够防水阻菌,并控制水蒸气透过率;下层为大孔层能够保持伤口湿性微环境、控制伤口渗出液、促进伤口愈合。
再一方面,本发明还提供上述细菌纤维素-聚氨酯复合材料在人体修复材料、智能药物缓释材料和组织工程材料中的应用。
本发明的有益效果:
(1)本发明采用细菌纤维素纳米纤维微纤与聚氨酯泡沫材料复合,显著提高了复合材料的力学性能;细菌纤维素纳米纤维表面大量羟基有效加强了复合材料的亲水性能及吸水能力;同时细菌纤维素良好的组织亲和能力可以改善聚氨酯材料的生物相容性;
(2)本发明通过聚氨酯反应中残留的异氰酸酯基团与细菌纤维素纳米纤维表面的羟基基团相互作用,以化学键合的方式使细菌纤维素纳米纤维与聚氨酯泡沫基体有效结合;
(3)本发明的制备工艺简单、成本低、无污染,得到的是一种环境友好可降解的细菌纤维素复合聚氨酯泡沫材料。该材料具有良好的生物相容性、力学性能、亲水/持水性能及吸水能力,在人体修复材料、智能药物缓释材料和组织工程材料等生物医用领域具有巨大的应用前景。
为了对本发明的技术特征、目的和有益效果有更加清楚的理解,现对本发明的技术方案进行以下详细说明,但不能理解为对本发明的可实施范围的限定。
下述实施例中所使用的实验方法如无特殊说明,均为常规方法。
下述实施例中所用的材料、试剂等,如无特殊说明,均可从商业途径得到。
实施例1
本实施提供一种细菌纤维素-聚氨酯复合材料的制备方法,其包括以下步骤:
步骤一,将木醋杆菌发酵培养得到的细菌纤维素浸泡在质量百分含量为4%的NaOH水溶液中,在100℃的温度下加热6h,再用蒸馏水反复冲洗至中性;然后采用高速分散机,25000rpm的转速下,对纯化的细菌纤维素样品均质10min,得到长度为0.1μm,直径为50nm的细菌纤维素微纤。
步骤二,将所述均质后的细菌纤维素微纤浸泡于无水乙醇中8h,以保证细菌纤维素微纤完全脱水,然后将脱水后的细菌纤维素微纤浸泡于有机溶剂乙基乙二醇乙酸酯中 48h,配制获得复合物A,所述复合物A以重量份为100wt%计,包括30wt%的细菌纤维素微纤和余量的有机溶剂(余量的有机溶剂中包括有残余的无水乙醇和乙基乙二醇乙酸酯)。
将所述均质后的细菌纤维素微纤浸泡于无水乙醇中3h,以脱除细菌纤维素微纤中的大部分水,然后将部分脱水后的细菌纤维素微纤浸泡于有机溶剂乙酸和丙酮中12h,配制获得复合物B,所述复合物B以重量份为100wt%计,包括15wt%的部分脱水的细菌纤维素微纤和余量的有机溶剂(余量的有机溶剂中包括有残余的无水乙醇、乙酸和丙酮);其中部分脱水的细菌纤维素微纤中含有5wt%的水。
步骤三,将复合物A和复合物B以体积比为1:2进行混合,在70℃的恒温油浴条件下,加入聚合物多元醇,并加入少量二异氰酸酯类化合物进行加聚反应,搅拌反应时间为60min,反应得到细菌纤维素复合聚氨酯泡沫预聚体。其中聚合物多元醇加入量是复合物A和复合物B混合后的总质量的20%。
步骤四,向细菌纤维素复合聚氨酯泡沫预聚体中加入固化助剂(催化剂+开孔剂+稳定剂)并搅拌均匀,然后加入二异氰酸酯类化合物和水高速搅拌并置于模具中,常温下静置固化2天得到该细菌纤维素-聚氨酯复合材料。
用量:加入的聚合物多元醇为聚乙二醇按100份重量计,加入的二异氰酸酯类化合物为甲苯二异氰酸酯,总量按60份重量计,其中先加入少量的二异氰酸酯类化合物占该物质总重量的20%,加入水重量按5份重量计。
加入的固化助剂包括催化剂、开孔剂和稳定剂;其中催化剂为三亚乙基二胺,用量为细菌纤维素复合聚氨酯泡沫预聚体用量的0.3wt%;开孔剂为开孔硅油,用量为细菌纤维素复合聚氨酯泡沫预聚体用量的1wt%;稳定剂为有机硅表面活性剂,用量为细菌纤维素复合聚氨酯泡沫预聚体用量的0.5wt%。
该细菌纤维素-聚氨酯复合材料具有不同孔径的梯度双层结构,一层为大孔层,大孔孔径为100μm,孔隙率为70%,厚度为0.5cm;另一层为微孔层,孔径为10μm,孔隙率为60%,厚度为0.1cm。该细菌纤维素-聚氨酯复合材料是由大孔层与微孔层构成的有机整体,在使用过程中上层为微孔层能够防水阻菌,并控制水蒸气透过率;下层为大孔层能够保持伤口湿性微环境、控制伤口渗出液、促进伤口愈合。
实施例2
本实施提供一种细菌纤维素-聚氨酯复合材料的制备方法,其包括以下步骤:
步骤一,将根瘤菌属与八叠球菌属发酵培养得到的细菌纤维素浸泡在质量百分含量 为5%的NaOH水溶液中,在90℃的温度下加热5h,再用蒸馏水反复冲洗至中性;然后采用高速分散机,20000rpm的转速下,对纯化的细菌纤维素样品均质5min,得到长度为2μm,直径为60nm的细菌纤维素微纤。
步骤二,将所述均质后的细菌纤维素微纤浸泡于无水乙醇中10h,以保证细菌纤维素微纤完全脱水,然后将脱水后的细菌纤维素微纤浸泡于有机溶剂乙酸乙酯中36h,配制获得复合物A,所述复合物A以重量份为100wt%计,包括40wt%的细菌纤维素微纤和余量的有机溶剂(余量的有机溶剂中包括有残余的无水乙醇和乙酸乙酯)。
将所述均质后的细菌纤维素微纤浸泡于无水乙醇中4h,以脱除细菌纤维素微纤中的大部分水,然后将部分脱水后的细菌纤维素微纤浸泡于有机溶剂丙酮中48h,配制获得复合物B,所述复合物B以重量份为100wt%计,包括20wt%的部分脱水的细菌纤维素微纤和余量的有机溶剂(余量的有机溶剂中包括有残余的无水乙醇和丙酮);其中部分脱水的细菌纤维素微纤中含有5wt%的水。
步骤三,将复合物A和复合物B以体积比为1:3进行混合,在70℃的恒温油浴条件下,加入聚合物多元醇,并加入少量二异氰酸酯类化合物进行加聚反应,搅拌反应时间为70min,反应得到细菌纤维素复合聚氨酯泡沫预聚体。其中聚合物多元醇加入量是复合物A和复合物B混合后的总质量的30%。
步骤四,向细菌纤维素复合聚氨酯泡沫预聚体中加入固化助剂(催化剂+开孔剂+稳定剂)并搅拌均匀,然后加入二异氰酸酯类化合物和水高速搅拌并置于模具中,常温下静置固化3天得到该细菌纤维素-聚氨酯复合材料。
用量:加入的聚合物多元醇为聚环氧丙烷按100份重量计,加入的二异氰酸酯类化合物为二苯基甲烷二异氰酸酯总量按60份重量计,其中先加入少量的二异氰酸酯类化合物占该物质总重量的20%,加入水重量按4份重量。
加入的固化助剂包括催化剂、开孔剂和稳定剂;其中催化剂为二甲基乙醇胺,用量为细菌纤维素复合聚氨酯泡沫预聚体用量的0.7wt%;开孔剂为硅油6070,用量为细菌纤维素复合聚氨酯泡沫预聚体用量的0.8wt%;稳定剂为椰油酰两性基乙酸钠,用量为细菌纤维素复合聚氨酯泡沫预聚体用量的0.4wt%。
该细菌纤维素-聚氨酯复合材料具有不同孔径的梯度双层结构,一层为大孔层,大孔孔径为200um,孔隙率为70%,厚度为0.7cm;另一层为微孔层,孔径为20μm,孔隙率为60%,厚度为0.1cm。该细菌纤维素-聚氨酯复合材料是由大孔层与微孔层构成的有机整体,在使用过程中上层为微孔层能够防水阻菌,并控制水蒸气透过率;下层为大 孔层能够保持伤口湿性微环境、控制伤口渗出液、促进伤口愈合。
实施例3
本实施提供一种细菌纤维素-聚氨酯复合材料的制备方法,其包括以下步骤:
步骤一,将假单胞菌属与无色杆菌属发酵培养得到的细菌纤维素浸泡在质量百分含量为6%的NaOH水溶液中,在80℃的温度下加热4h,再用蒸馏水反复冲洗至中性;然后采用高速分散机,25000rpm的转速下,对纯化的细菌纤维素样品均质6min,得到长度为4μm,直径为70nm的细菌纤维素微纤。
步骤二,将所述均质后的细菌纤维素微纤浸泡于无水乙醇中9h,以保证细菌纤维素微纤完全脱水,然后将脱水后的细菌纤维素微纤浸泡于有机溶剂丁内酯中72h,配制获得复合物A,所述复合物A以重量份为100wt%计,包括50wt%的细菌纤维素微纤和余量的有机溶剂(余量的有机溶剂中包括有残余的无水乙醇和丁内酯)。
将所述均质后的细菌纤维素微纤浸泡于无水乙醇中5h,以脱除细菌纤维素微纤中的大部分水,然后将部分脱水后的细菌纤维素微纤浸泡于有机溶剂乙基乙二醇乙酸酯中12h,配制获得复合物B,所述复合物B以重量份为100wt%计,包括30wt%的部分脱水的细菌纤维素微纤和余量的有机溶剂(余量的有机溶剂中包括有残余的无水乙醇和乙基乙二醇乙酸酯);其中部分脱水的细菌纤维素微纤中含有10wt%的水。
步骤三,将复合物A和复合物B以体积比为1:4进行混合,在70℃的恒温油浴条件下,加入聚合物多元醇,并加入少量二异氰酸酯类化合物进行加聚反应,搅拌反应时间为60min,反应得到细菌纤维素复合聚氨酯泡沫预聚体。其中聚合物多元醇加入量是复合物A和复合物B混合后的总质量的40%。
步骤四,向细菌纤维素复合聚氨酯泡沫预聚体中加入固化助剂(催化剂+开孔剂+稳定剂)并搅拌均匀,然后加入二异氰酸酯类化合物和水高速搅拌并置于模具中,常温下静置固化4天得到该细菌纤维素-聚氨酯复合材料。
用量:加入的聚合物多元醇为丙二醇和一缩二乙二醇总量(1:1)按100份重量计,加入的二异氰酸酯类化合物为异佛尔酮二异氰酸酯总量按50份重量计,其中先加入少量的二异氰酸酯类化合物占该物质总重量的20%,加入水重量按3份重量。
加入的固化助剂包括催化剂、开孔剂和稳定剂;其中催化剂为二月桂酸二丁基锡,用量为细菌纤维素复合聚氨酯泡沫预聚体用量的0.9wt%;开孔剂为聚丁二烯二醇,用量为细菌纤维素复合聚氨酯泡沫预聚体用量的0.5wt%;稳定剂为桂酰两性基乙酸钠用量为细菌纤维素复合聚氨酯泡沫预聚体用量的0.3wt%。
该细菌纤维素-聚氨酯复合材料具有不同孔径的梯度双层结构,一层为大孔层,大孔的孔径为300μm,孔隙率为80%,厚度为0.8cm;另一层为微孔层,孔径为40μm,孔隙率为70%,厚度为0.2cm。该细菌纤维素-聚氨酯复合材料是由大孔层与微孔层构成的有机整体,在使用过程中上层为微孔层能够防水阻菌,并控制水蒸气透过率;下层为大孔层能够保持伤口湿性微环境、控制伤口渗出液、促进伤口愈合。
实施例4
本实施提供一种细菌纤维素-聚氨酯复合材料的制备方法,其包括以下步骤:
步骤一,将产碱菌属、气杆菌属和固氮菌属混合发酵培养得到的细菌纤维素浸泡在质量百分含量为7%的NaOH水溶液中,在70℃的温度下加热4h,再用蒸馏水反复冲洗至中性;然后采用高速分散机,15000rpm的转速下,对纯化的细菌纤维素样品均质8min,得到长度为6μm,直径为80nm的细菌纤维素微纤。
步骤二,将所述均质后的细菌纤维素微纤浸泡于无水乙醇中10h,以保证细菌纤维素微纤完全脱水,然后将脱水后的细菌纤维素微纤浸泡于有机溶剂乙酸和丙酮中36h,配制获得复合物A,所述复合物A以重量份为100wt%计,包括30wt%的细菌纤维素微纤和余量的有机溶剂(余量的有机溶剂中包括有残余的无水乙醇、乙酸和丙酮)。
将所述均质后的细菌纤维素微纤浸泡于无水乙醇中6h,以脱除细菌纤维素微纤中的大部分水,然后将部分脱水后的细菌纤维素微纤浸泡于有机溶剂丙酮中12h,配制获得复合物B,所述复合物B以重量份为100wt%计,包括23wt%的部分脱水的细菌纤维素微纤和余量的有机溶剂(余量的有机溶剂中包括有残余的无水乙醇和丙酮);其中部分脱水的细菌纤维素微纤中含有8wt%的水。
步骤三,将复合物A和复合物B以体积比为1:5进行混合,在80℃的恒温油浴条件下,加入聚合物多元醇,并加入少量二异氰酸酯类化合物进行加聚反应,搅拌反应时间为70min,反应得到细菌纤维素复合聚氨酯泡沫预聚体。其中聚合物多元醇加入量是复合物A和复合物B混合后的总质量的50%。
步骤四,向细菌纤维素复合聚氨酯泡沫预聚体中加入固化助剂(催化剂+开孔剂+稳定剂)并搅拌均匀,然后加入二异氰酸酯类化合物和水高速搅拌并置于模具中,常温下静置固化5天得到该细菌纤维素-聚氨酯复合材料。
用量:加入的聚合物多元醇为聚乙二醇和聚环氧丙烷(1:1)总量按100份重量计,加入的二异氰酸酯类化合物为甲苯二异氰酸酯和二苯基甲烷二异氰酸酯(1:1)总量按50份重量计,其中先加入少量的二异氰酸酯类化合物占该物质总重量的10%,加入水 重量按2份重量。
加入的固化助剂包括催化剂、开孔剂和稳定剂;其中催化剂为三亚乙基二胺和辛酸亚锡(1:1)用量为细菌纤维素复合聚氨酯泡沫预聚体用量的1.0wt%;开孔剂为开孔硅油和硅油6070(1:1),用量为细菌纤维素复合聚氨酯泡沫预聚体用量的0.5wt%;稳定剂为月桂酰两性基二乙酸二钠,用量为细菌纤维素复合聚氨酯泡沫预聚体用量的0.2wt%。
该细菌纤维素-聚氨酯复合材料具有不同孔径的梯度双层结构,一层为大孔层,大孔孔径为300μm,孔隙率为80%,厚度为0.6cm;另一层为微孔层,孔径为50μm,孔隙率为70%,厚度为0.2cm。该细菌纤维素-聚氨酯复合材料是由大孔层与微孔层构成的有机整体,在使用过程中上层为微孔层能够防水阻菌,并控制水蒸气透过率;下层为大孔层能够保持伤口湿性微环境、控制伤口渗出液、促进伤口愈合。
实施例5
本实施提供一种细菌纤维素-聚氨酯复合材料的制备方法,其包括以下步骤:
步骤一,将木醋杆菌与假单胞菌属发酵培养得到的细菌纤维素浸泡在质量百分含量为6%的NaOH水溶液中,在100℃的温度下加热5h,再用蒸馏水反复冲洗至中性;然后采用高速分散机,10000rpm的转速下,对纯化的细菌纤维素样品均质9min,得到长度为8μm,直径为90nm的细菌纤维素微纤。
步骤二,将所述均质后的细菌纤维素微纤浸泡于无水乙醇中11h,以保证细菌纤维素微纤完全脱水,然后将脱水后的细菌纤维素微纤浸泡于有机溶剂乙基乙二醇乙酸酯和乙酸乙酯中48h,配制获得复合物A,所述复合物A以重量份为100wt%计,包括40wt%的细菌纤维素微纤和余量的有机溶剂(余量的有机溶剂中包括有残余的无水乙醇、乙基乙二醇乙酸酯和乙酸乙酯)。
将所述均质后的细菌纤维素微纤浸泡于无水乙醇中7h,以脱除细菌纤维素微纤中的大部分水,然后将部分脱水后的细菌纤维素微纤浸泡于有机溶剂乙基乙二醇乙酸酯中36h,配制获得复合物B,所述复合物B以重量份为100wt%计,包括26wt%的部分脱水的细菌纤维素微纤和余量的有机溶剂(余量的有机溶剂中包括有残余的无水乙醇和乙基乙二醇乙酸酯);其中部分脱水的细菌纤维素微纤中含有6wt%的水。
步骤三,将复合物A和复合物B以体积比为1:3进行混合,在80℃的恒温油浴条件下,加入聚合物多元醇,并加入少量二异氰酸酯类化合物进行加聚反应,搅拌反应时间为80min,反应得到细菌纤维素复合聚氨酯泡沫预聚体。其中聚合物多元醇加入量是 复合物A和复合物B混合后的总质量的60%。
步骤四,向细菌纤维素复合聚氨酯泡沫预聚体中加入固化助剂(催化剂+开孔剂+稳定剂)并搅拌均匀,然后加入二异氰酸酯类化合物和水高速搅拌并置于模具中,常温下静置固化6天得到该细菌纤维素-聚氨酯复合材料。
用量:加入的聚合物多元醇为聚乙二醇和丙二醇(2:1)按100份重量计,加入的二异氰酸酯类化合物为二苯基甲烷二异氰酸酯和异佛尔酮二异氰酸酯(1:1)总量按40份重量计,其中先加入少量的二异氰酸酯类化合物占该物质总重量的10%,加入水重量按3份重量。
加入的固化助剂包括催化剂、开孔剂和稳定剂;其中催化剂为二甲基乙醇胺和辛酸亚锡(1:1)用量为细菌纤维素复合聚氨酯泡沫预聚体用量的1.2wt%;开孔剂为包括开孔硅油和聚丁二烯二醇(2:1),用量为细菌纤维素复合聚氨酯泡沫预聚体用量的0.3wt%;稳定剂为有机硅表面活性剂和椰油酰两性基乙酸钠(1:1)用量为细菌纤维素复合聚氨酯泡沫预聚体用量的0.1wt%。
该细菌纤维素-聚氨酯复合材料具有不同孔径的梯度双层结构,一层为大孔层,大孔孔径为400μm,孔隙率为90%,厚度为0.9cm;另一层为微孔层,孔径为60μm,孔隙率为80%,厚度为0.3cm。该细菌纤维素-聚氨酯复合材料是由大孔层与微孔层构成的有机整体,在使用过程中上层为微孔层能够防水阻菌,并控制水蒸气透过率;下层为大孔层能够保持伤口湿性微环境、控制伤口渗出液、促进伤口愈合。
实施例6
本实施提供一种细菌纤维素-聚氨酯复合材料的制备方法,其包括以下步骤:
步骤一,将木醋杆菌发酵培养得到的细菌纤维素浸泡在质量百分含量为8%的NaOH水溶液中,在80℃的温度下加热6h,再用蒸馏水反复冲洗至中性;然后采用高速分散机,5000rpm的转速下,对纯化的细菌纤维素样品均质10min,得到长度为10μm,直径为100nm的细菌纤维素微纤。
步骤二,将所述均质后的细菌纤维素微纤浸泡于无水乙醇中12h,以保证细菌纤维素微纤完全脱水,然后将脱水后的细菌纤维素微纤浸泡于有机溶剂乙酸乙酯和丙酮中72h,配制获得复合物A,所述复合物A以重量份为100wt%计,包括50wt%的细菌纤维素微纤和余量的有机溶剂(余量的有机溶剂中包括有残余的无水乙醇和乙酸乙酯)。
将所述均质后的细菌纤维素微纤浸泡于无水乙醇中6h,以脱除细菌纤维素微纤中的大部分水,然后将部分脱水后的细菌纤维素微纤浸泡于有机溶剂乙酸乙酯中48h,配制 获得复合物B,所述复合物B以重量份为100wt%计,包括30wt%的部分脱水的细菌纤维素微纤和余量的有机溶剂(余量的有机溶剂中包括有残余的无水乙醇和乙酸乙酯);其中部分脱水的细菌纤维素微纤中含有10wt%的水。
步骤三,将复合物A和复合物B以体积比为1:2进行混合,在80℃的恒温油浴条件下,加入聚合物多元醇,并加入少量二异氰酸酯类化合物进行加聚反应,搅拌反应时间为90min,反应得到细菌纤维素复合聚氨酯泡沫预聚体。其中聚合物多元醇加入量是复合物A和复合物B混合后的总质量的40%。
步骤四,向细菌纤维素复合聚氨酯泡沫预聚体中加入固化助剂(催化剂+开孔剂+稳定剂)并搅拌均匀,然后加入二异氰酸酯类化合物和水高速搅拌并置于模具中,常温下静置固化7天得到该细菌纤维素-聚氨酯复合材料。
用量:加入的聚合物多元醇为聚乙二醇按100份重量计,加入的二异氰酸酯类化合物为甲苯二异氰酸酯和异佛尔酮二异氰酸酯(4:1)总量按40份重量计,其中先加入少量的二异氰酸酯类化合物占该物质总重量的10%;加入水重量按4份重量。
加入的固化助剂包括催化剂、开孔剂和稳定剂;其中催化剂为二月桂酸二丁基锡和辛酸亚锡(1:1)用量为细菌纤维素复合聚氨酯泡沫预聚体用量的1.5wt%;开孔剂为开孔硅油、硅油6070和聚丁二烯二醇中(2:1:1),用量为细菌纤维素复合聚氨酯泡沫预聚体用量的0.1wt%;稳定剂为椰油酰两性基乙酸钠、桂酰两性基乙酸钠和月桂酰两性基二乙酸二钠(1:1:1),用量为细菌纤维素复合聚氨酯泡沫预聚体用量的0.1wt%。
该细菌纤维素-聚氨酯复合材料具有不同孔径的梯度双层结构,一层为大孔层,大孔孔径为500μm,孔隙率为90%,厚度为1cm;另一层为微孔层,孔径为80μm,孔隙率为80%,厚度为0.3cm。该细菌纤维素-聚氨酯复合材料是由大孔层与微孔层构成的有机整体,在使用过程中上层为微孔层能够防水阻菌,并控制水蒸气透过率;下层为大孔层能够保持伤口湿性微环境、控制伤口渗出液、促进伤口愈合。
性能测试实验:
对实施例制备的细菌纤维素-聚氨酯复合材料进行了如下性能测试:
透气膜敷料水蒸气透过率实验:按照YY/T 0471.2-2004《接触性创面敷料试验方法第2部分:透气膜敷料水蒸气透过率》对细菌纤维素-聚氨酯复合材料的水蒸气透过率进行测试,水蒸气透过率(MVTR)为1600克每平方米每24小时(g·m
-2·24h
-1)。
生物相容性实验:参照GB/T 16886医疗器械的生物学评价,分别对细菌纤维素-聚氨酯复合材料进行细胞毒性、豚鼠迟发接触性致敏、皮肤刺激等评价。
生物相容性评价:细胞内毒性试验按照GB/T 16886-5《医疗器械生物学评价第5部分:体外细胞毒性试验》进行测试;豚鼠迟发型接触致敏试验按照GB/T 16886-10《医疗器械生物学评价第10部分:刺激与迟发型超敏反应试验》进行测试,采用最大限度试验Magnusson和Kligman法。皮肤刺激试验按照GB/T 16886-10《医疗器械生物学评价第10部分:刺激与迟发型超敏反应试验》进行测试。
结果表明:本发明上述实施例制备获得的细菌纤维素-聚氨酯复合材料细胞毒性小于2级,无皮肤致敏反应,无皮内刺激反应,具有良好的生物安全性。
Claims (15)
- 一种细菌纤维素-聚氨酯复合材料的制备方法,其包括以下步骤:将细菌纤维素微纤进行有机溶剂交换处理,获得不同浓度的细菌纤维素微纤的复合物A和复合物B;其中,所述复合物A以重量份为100wt%计,包括30~50wt%的完全脱水的细菌纤维素微纤和余量的有机溶剂;所述复合物B以重量份为100wt%计,包括15~30wt%的部分脱水的细菌纤维素微纤和余量的有机溶剂;其中,部分脱水的细菌纤维素微纤中含有5~10wt%的水;将复合物A和复合物B以体积比为1:(2~5)进行混合,于油浴条件下加入聚合物多元醇和二异氰酸酯类化合物进行加聚反应,反应得到细菌纤维素复合聚氨酯泡沫预聚体;将其固化后得到细菌纤维素-聚氨酯复合材料;其中,所述聚合物多元醇和所述二异氰酸酯类化合物的重量比为1:(0.1~0.2);所述聚合物多元醇占所述复合物A和所述复合物B总重量的20%~60%。
- 根据权利要求1所述的方法,其还包括将菌株发酵得到的细菌纤维素进行纯化、均质处理得到细菌纤维素微纤的过程;其中,所述菌株包括木醋杆菌、根瘤菌属、八叠球菌属、假单胞菌属、无色杆菌属、产碱菌属、气杆菌属和固氮菌属中的一种或多种的组合。
- 根据权利要求1所述的方法,其还包括将菌株发酵得到的细菌纤维素进行纯化、均质处理得到细菌纤维素微纤的过程;其中,对细菌纤维素进行纯化的方法包括:于70℃~100℃的温度下,将细菌纤维素在质量百分含量为4%~8%的氢氧化钠水溶液中洗涤4~6h,再用蒸馏水反复冲洗至中性,以除去细菌纤维素上的菌体蛋白和粘附在纤维素膜上的残余培养基,获得纯化后的细菌纤维素。
- 根据权利要求3所述的方法,其中,对细菌纤维素进行均质处理的方法为:采用高速分散机于5000~25000rpm的转速下,对纯化后的细菌纤维素均质5~10min,得到细菌纤维素微纤。
- 根据权利要求1所述的方法,其中,所述细菌纤维素微纤的长度为0.1~10μm,直径为50~100nm。
- 根据权利要求1所述的方法,其中,所述有机溶剂交换处理的方法为:将细菌纤维素微纤浸泡于无水乙醇中,通过控制浸泡时间8-12h获得完全脱水后的细菌纤维素微纤和控制浸泡时间3-6h获得部分脱水后的细菌纤维素微纤;将完全脱水后的细菌纤维素微纤浸泡于有机溶剂中48~72h,获得复合物A;将部分脱水后的细菌纤维素微纤浸泡于有机溶剂中12~48h,获得复合物B。
- 根据权利要求1或6所述的方法,其中,所述有机溶剂包括乙基乙二醇乙酸酯、乙酸乙酯、丁内酯、乙酸和丙酮中的一种或多种的组合。
- 根据权利要求1所述的方法,其中,进行加聚反应的条件为:70℃~80℃下恒温油浴,反应时间为60~90min;优选地,所述聚合物多元醇包括聚乙二醇、聚环氧丙烷、丙二醇和一缩二乙二醇中的一种或多种的组合。
- 根据权利要求1所述的方法,其中,对所述细菌纤维素复合聚氨酯泡沫预聚体进行固化的方法为:向细菌纤维素复合聚氨酯泡沫预聚体中加入固化助剂并搅拌均匀,然后加入二异氰酸酯类化合物和水并搅拌均匀得到混合物,然后固化得到细菌纤维素-聚氨酯复合材料;所述固化助剂的用量为细菌纤维素复合聚氨酯泡沫预聚体用量的0.5~2.6wt%;所述二异氰酸酯类化合物和水的用量比为(20~40):(2~5);固化中,所述二异氰酸酯类化合物的用量为所述聚合物多元醇用量的20%~50%;优选地,所述二异氰酸酯类化合物包括甲苯二异氰酸酯、二苯基甲烷二异氰酸酯和异佛尔酮二异氰酸酯中的一种或多种的组合;优选地,所述固化助剂包括催化剂、开孔剂和稳定剂;所述催化剂包括三亚乙基二胺、二甲基乙醇胺、二月桂酸二丁基锡和辛酸亚锡中的一种或多种的组合;所述开孔剂包括开孔硅油、硅油6070和聚丁二烯二醇中的一种或多种的组合;所述稳定剂包括有机硅表面活性剂、椰油酰两性基乙酸钠、桂酰两性基乙酸钠和月桂酰两性基二乙酸二钠中的一种或多种的组合。
- 根据权利要求9所述的方法,其中,所述催化剂的用量为细菌纤维素复合聚氨酯泡沫预聚体用量的0.3~1.5wt%;所述开孔剂的用量为细菌纤维素复合聚氨酯泡沫预聚体用量的0.1~1wt%;所述稳定剂的用量为细菌纤维素复合聚氨酯泡沫预聚体用量的0.1~0.5wt%。
- 根据权利要求9所述的方法,其中,所述固化是将混合搅拌均匀的混合物置于模具中,于室温条件下静置2~7d。
- 一种细菌纤维素-聚氨酯复合材料,其包括大孔层和微孔层至少两层结构,大孔 层的孔径为100~500μm,孔隙率为70%~90%,厚度为0.5~1cm;微孔层的孔径为10~80μm,孔隙率为60%~80%;厚度为0.1~0.3cm。
- 根据权利要求12所述的细菌纤维素-聚氨酯复合材料,其是采用权利要求1-11任一项所述制备方法制备获得的。
- 根据权利要求12所述的细菌纤维素-聚氨酯复合材料,其中,所述细菌纤维素微纤在复合材料中的质量占比为20~40wt%。
- 权利要求12-14任一项所述细菌纤维素-聚氨酯复合材料在人体修复材料、智能药物缓释材料和组织工程材料中的应用。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2019/129157 WO2021128272A1 (zh) | 2019-12-27 | 2019-12-27 | 一种细菌纤维素-聚氨酯复合材料及其制备方法和应用 |
JP2022539109A JP7425877B2 (ja) | 2019-12-27 | 2019-12-27 | バクテリアセルロース/ポリウレタン複合材料及びその製造方法 |
US17/847,455 US20220315760A1 (en) | 2019-12-27 | 2022-06-23 | Bacterial Cellulose-Polyurethane Composite Material, Preparation Method Therefor, and Application Thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2019/129157 WO2021128272A1 (zh) | 2019-12-27 | 2019-12-27 | 一种细菌纤维素-聚氨酯复合材料及其制备方法和应用 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/847,455 Continuation US20220315760A1 (en) | 2019-12-27 | 2022-06-23 | Bacterial Cellulose-Polyurethane Composite Material, Preparation Method Therefor, and Application Thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021128272A1 true WO2021128272A1 (zh) | 2021-07-01 |
Family
ID=76573562
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2019/129157 WO2021128272A1 (zh) | 2019-12-27 | 2019-12-27 | 一种细菌纤维素-聚氨酯复合材料及其制备方法和应用 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20220315760A1 (zh) |
JP (1) | JP7425877B2 (zh) |
WO (1) | WO2021128272A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023218225A1 (en) | 2022-05-12 | 2023-11-16 | Polybion, S.L. | Composite material comprising polyurethane and tanned bacterial cellulose, and method for manufacturing the same |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116284968A (zh) * | 2023-03-24 | 2023-06-23 | 四川大学华西医院 | 形状记忆聚氨酯/生物质纤维复合泡沫无溶剂制备及其调控足底压力的方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103370190A (zh) * | 2010-09-07 | 2013-10-23 | 耶路撒冷希伯来大学伊森姆研究发展有限公司 | 基于纤维素的复合材料 |
CN104592743A (zh) * | 2015-02-03 | 2015-05-06 | 东北林业大学 | 一种纳米纤维素/聚氨酯泡沫复合弹性体的制备方法 |
WO2016047981A1 (ko) * | 2014-09-22 | 2016-03-31 | 주식회사 제네웰 | 창상피복 조성물 및 창상피복재 |
CN109069688A (zh) * | 2016-04-08 | 2018-12-21 | 墨尼克医疗用品有限公司 | 伤口处理中的复合材料 |
CN110269749A (zh) * | 2019-05-22 | 2019-09-24 | 东华大学 | 一种维持伤口适度湿润的定向导液敷料及其制备方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6368093A (ja) * | 1986-09-08 | 1988-03-26 | Daicel Chem Ind Ltd | 微生物生産セルロ−スの分離回収方法 |
JPH1095803A (ja) * | 1995-11-02 | 1998-04-14 | Bio Polymer Res:Kk | セルロース被膜及びその形成方法 |
JP5577622B2 (ja) * | 2008-05-13 | 2014-08-27 | 三菱化学株式会社 | 微細セルロース繊維分散液、高分子セルロース複合体及びセルロース繊維の解繊方法 |
JP2011094003A (ja) * | 2009-10-29 | 2011-05-12 | Sanyo Chem Ind Ltd | ポリウレタン樹脂製造用活性水素成分 |
JP7176849B2 (ja) * | 2018-03-23 | 2022-11-22 | 株式会社イノアックコーポレーション | ポリウレタンフォーム組成物とポリウレタンフォームの製造方法 |
-
2019
- 2019-12-27 WO PCT/CN2019/129157 patent/WO2021128272A1/zh active Application Filing
- 2019-12-27 JP JP2022539109A patent/JP7425877B2/ja active Active
-
2022
- 2022-06-23 US US17/847,455 patent/US20220315760A1/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103370190A (zh) * | 2010-09-07 | 2013-10-23 | 耶路撒冷希伯来大学伊森姆研究发展有限公司 | 基于纤维素的复合材料 |
WO2016047981A1 (ko) * | 2014-09-22 | 2016-03-31 | 주식회사 제네웰 | 창상피복 조성물 및 창상피복재 |
CN104592743A (zh) * | 2015-02-03 | 2015-05-06 | 东北林业大学 | 一种纳米纤维素/聚氨酯泡沫复合弹性体的制备方法 |
CN109069688A (zh) * | 2016-04-08 | 2018-12-21 | 墨尼克医疗用品有限公司 | 伤口处理中的复合材料 |
CN110269749A (zh) * | 2019-05-22 | 2019-09-24 | 东华大学 | 一种维持伤口适度湿润的定向导液敷料及其制备方法 |
Non-Patent Citations (1)
Title |
---|
PINTO ELAINE R. P., BARUD HERNANE S., POLITO WAGNER LUIZ, RIBEIRO SIDNEY J. L., MESSADDEQ YOUNÈS: "Preparation and characterization of the bacterial cellulose/polyurethane nanocomposites", JOURNAL OF THERMAL ANALYSIS AND CALORIMETRY, KLUWER, DORDRECHT,, NL, vol. 114, no. 2, 1 November 2013 (2013-11-01), NL, pages 549 - 555, XP055823952, ISSN: 1388-6150, DOI: 10.1007/s10973-013-3001-y * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023218225A1 (en) | 2022-05-12 | 2023-11-16 | Polybion, S.L. | Composite material comprising polyurethane and tanned bacterial cellulose, and method for manufacturing the same |
Also Published As
Publication number | Publication date |
---|---|
US20220315760A1 (en) | 2022-10-06 |
JP7425877B2 (ja) | 2024-01-31 |
JP2023508423A (ja) | 2023-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhang et al. | Zn2+-loaded TOBC nanofiber-reinforced biomimetic calcium alginate hydrogel for antibacterial wound dressing | |
Feng et al. | Mechanically robust and flexible silk protein/polysaccharide composite sponges for wound dressing | |
Fu et al. | Present status and applications of bacterial cellulose-based materials for skin tissue repair | |
CN113603860B (zh) | 一种细菌纤维素-聚氨酯复合材料及其制备方法和应用 | |
CN111303449B (zh) | 可降解的电活性细菌纤维素/MXene复合水凝胶及制备与应用 | |
Lina et al. | Bacterial cellulose for skin repair materials | |
Naghshineh et al. | Preparation of chitosan, sodium alginate, gelatin and collagen biodegradable sponge composites and their application in wound healing and curcumin delivery | |
CN108912352A (zh) | 一种抗菌粘附可注射水凝胶敷料及其制备方法和应用 | |
US20220315760A1 (en) | Bacterial Cellulose-Polyurethane Composite Material, Preparation Method Therefor, and Application Thereof | |
Zhang et al. | Bioactive composite Janus nanofibrous membranes loading Ciprofloxacin and Astaxanthin for enhanced healing of full-thickness skin defect wounds | |
Yuan et al. | A cellulose/Konjac glucomannan–based macroporous antibacterial wound dressing with synergistic and complementary effects for accelerated wound healing | |
CN101570616A (zh) | 一种细菌纤维素/聚乙烯醇复合凝胶材料及其制备方法 | |
CN1235646C (zh) | 一种多功能生物修复材料的制备方法 | |
CN114225096A (zh) | 一种促进伤口愈合的复合水凝胶及其制备方法和应用 | |
Ye et al. | Surface Modification of Electrospun TPU Nanofiber Scaffold with CNF Particles by Ultrasound‐Assisted Technique for Tissue Engineering | |
CN104906623A (zh) | 一种纤维素基敷料及其制备方法和应用 | |
CN106620832A (zh) | 一种透明抗菌水凝胶敷料、其制备方法和应用 | |
CN115282319B (zh) | 人工肌肉纤维、其制备方法及伤口愈合敷料 | |
Zhang et al. | Self-assembly of chitosan and cellulose chains into a 3D porous polysaccharide alloy films: Co-dissolving, structure and biological properties | |
Lee et al. | Cellulose/poly-(m-phenylene isophthalamide) porous film as a tissue-engineered skin bioconstruct | |
CN113529419B (zh) | 负载纳米氧化锌的细菌纤维素微纤-海藻酸纤维复合材料 | |
Li et al. | Construction of porous structure-based carboxymethyl chitosan/sodium alginate/tea polyphenols for wound dressing | |
Zhang et al. | Fabrication of a high-toughness polyurethane/fibroin composite without interfacial treatment and its toughening mechanism | |
Ding et al. | The esterified lentinan bilayer nanofibrous membrane for promoting wound healing | |
WO2021138790A1 (zh) | 负载纳米氧化锌的细菌纤维素微纤-海藻酸纤维复合材料 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19957214 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022539109 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 19957214 Country of ref document: EP Kind code of ref document: A1 |